Abstract
Lentinan obtained from the fruit-body of Lentinus edodes, the most popular edible mushroom in Japan, is a fully purified β-1,6;β-1,3-D-glucan, and its physicochemical properties are strictly characterized (1-3). This polysaccharide has prominent antitumor activity in syngeneic and even autologous hosts, and its immunopharmacological characteristics are well defined as T-cell oriented immunopotentiators different from the well-known immunostimulants such as BCG, C. parvum, LPS or levamisole. Lentinan appears to represent an unique class of immunological adjuvant and has only little toxic side effects. Therefore, lentinan is worth considering as one of the most useful immunopotentiators for cancer patients, and this article concerns preclinical evaluation of lentinan in experimental and animal models for cancer immunotherapy in humans.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chihara, G., J. Hamuro, Y. Y. Hamuro, Y. Arai and F. Fukuoka. 1970. Fractionation and purification of the polysaccharides with marked antitumour activity, especially lentinan, from Lentinus edodes (Berk.) Sing., an edible mushroom. Cancer Res. 30: 2776.
Chihara, G. 1981. The antitumour polysaccharide lentinan: An overview, p. 1. In T. Aoki et al. (eds.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.
Hamuro, J., and G. Chihara. 1982. Iuuuunopotentiation by lentinan and its immunopharmacology. Chapter 14. In J. W. Hadden, A. Szentivanyi and J. R. Battisto (eds.), The pharmacology of the reticuloendothelial system. Plenum Press, New York, N.Y.
Zâkâny, J., G. Chihara and J. Fachet. 1980. Effect of lentinan on tumour growth in marine allogeneic and syngeneic hosts. Int. J. Cancer 25: 371.
Shiio, T., and Y. Yugari. 1981. The antitumour effect of lentinan and tumour recognition in mice p. 29. In T. Aoki et al. (ads.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.
Hamada, C. 1981. Inhibitory effect of lentinan on the tumourigenesis of adenovirus type-12 in mice p. 76, In T. Aoki et al. (eds.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.
Kanaí, K., E. Kondo, P. J. Jacques and G. Chihara. 1980. Immunopotentiating effect of fungal glucans as related by frequency limitation of post chemotherapy relapse in experimental mouse tuberculosis. Jap. J. Med. Sci. & Biol. 33: 283.
Chang, K. S. S. 1981. Lentinan-mediated resistance against VSV-encephalitis, Abelson virus-induced tumour, and trophoblastic tumour in mice, p. 88. In T. Aoki et al. (eds.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.
Byrum, J. E., A. Sher, J. DiPietro and F. von Lichitenberg. 1979. Potentiation of Shistosoma granuloma by lentinan, A T-cell adjuvant. Am. J. Pathol. 94: 201.
Haba, S., T. Hamaoka, K. Takatsu and M. Kitagawa. 1976. Selective suppression of T-cell activity in tumour bearing mice and its improvement by lentinan. Int. J. Cancer 18: 93.
Maeda, Y. Y., and G. Chihara. 1973. The effect of neonatal thymectomy on the antitumour activity of lentinan and their effects on various immune responses. Int. J. Cancer 11: 153.
Hamuro, J., M. Röllinghof and H. Wagner. 1980. Induction of cytotoxic PE-cells by T-cell immune adjuvant of the 8–1,3-glucan type lentinan and its analogues. Immunology 39: 551.
Maeda, Y. Y., G. Chihara and K. Ishimura. 1974. Unique increase of serum protein components and action of antitumour polysaccharides. Nature (London) New Biol. 252: 250.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer Science+Business Media New York
About this chapter
Cite this chapter
Chihara, G. (1983). Preclinical Evaluation of Lentinan in Animal Models. In: Klein, T., Specter, S., Friedman, H., Szentivanyi, A. (eds) Biological Response Modifiers in Human Oncology and Immunology. Advances in Experimental Medicine and Biology, vol 166. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1410-4_16
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1410-4_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1412-8
Online ISBN: 978-1-4757-1410-4
eBook Packages: Springer Book Archive